Popular GLP-1 obesity drugs face 'vision warning'... MFDS reviews safety

[Financial News] The Ministry of Food and Drug Safety (MFDS) has issued a safety warning over the potential side effects of GLP-1 obesity treatments. The move follows the confirmation of overseas safety information indicating that these medicines may increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION).
The MFDS said on the 11th that it had distributed a letter containing safety information on GLP-1 medicines to medical professionals and patients in Korea.
NAION is a condition that causes vision loss when problems arise in the blood flow supplying the optic nerve. The MFDS recommended that healthcare professionals discontinue treatment and that patients receive immediate medical attention if NAION is suspected in patients receiving GLP-1 medicines. It also advised patients to consult their doctor immediately if they develop related symptoms.
The medicines covered by this safety information include tirzepatide, semaglutide, liraglutide and efpeglenatide.
The MFDS asked pharmaceutical companies supplying GLP-1 medicines in Korea to submit information on the relevant safety findings and plans to revise the approved product information. It plans to review the submitted materials and decide whether to change the precautions for use.
The MFDS has been monitoring adverse events involving GLP-1 medicines and taking safety management measures, including changes to their approved product information. It plans to continue monitoring relevant safety information and take any necessary action.
[email protected] Jung Sang-hee Reporter